SCHEMBL6463245

SCHEMBL6463245

O=C(O)Cc1ccc(NC(=O)c2cc(-c3ccc(OC(F)(F)F)cc3)cs2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 7/20 0.56
ABL1 P00519 1/20 0.56
MMP13 P45452 1/20 0.55
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
NR1H4 Q96RI1 3/20 0.46
SCN10A Q9Y5Y9 1/20 0.45
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
RXRG P48443 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
EPHX2 P34913 1/20 0.44
SHMT2 P34897 1/20 0.44
TRPV1 Q8NER1 1/20 0.44
NLRP3 Q96P20 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450855 0.90 MMP12 (0.55) MMP12ABL1MMP13NR1H4SCN10A
SCHEMBL6456507 0.87 MMP12 (0.72) MMP12ABL1MMP13NR1H4RXRA
SCHEMBL8342310 0.87 MMP12 (0.59) MMP12ABL1MMP13MEN1KMT2A
SCHEMBL6152695 0.87 MMP12 (0.67) MMP12ABL1MMP13MEN1KMT2A
SCHEMBL6451843 0.86 POLB (0.60) MMP12MMP13MEN1KMT2AALDH1A1
SCHEMBL6451590 0.82 ABL1 (0.57) MMP12ABL1MMP13TP53SCN10A
SCHEMBL6141803 0.82 ABL1 (0.57) MMP12ABL1MMP13SCN10AEPHX2
SCHEMBL6880673 0.81 MMP12 (0.58) MMP12ABL1MMP13ALDH1A1SCN10A
SCHEMBL6455132 0.81 NR1H4 (0.64) MMP12MEN1KMT2AALDH1A1TP53
SCHEMBL6450834 0.81 ABL1 (0.54) MMP12ABL1MMP13KMT2ASCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534700-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2005-06-01 EP claimed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US claimed
WO-2004018448-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2004-03-04 WO claimed
EP-1394159-A1 New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them Warner-Lambert Company LLC (US) 2004-03-03 EP claimed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US disclosed
WO-2004018448-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them MMP11, MMP13, CBR1 MMP12 7/4885ABL1 2800/4885MMP13 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.